open access

Vol 88, No 6 (2017)
Research paper
Published online: 2017-06-30
Get Citation

Potentialization of N-a-tosyl-L-phenylalanine chloromethyl ketone (TPCK) cytotoxic activity by 2-(1-adamantylamino)-6-methylpyridine (AdAMP) in human ovarian cancer cells

Jacek Sieńko1, Witold Lasek2, Justyna Teliga-Czajkowska3, Roman Smolarczyk4, Krzysztof Czajkowski5
DOI: 10.5603/GP.a2017.0064
·
Pubmed: 28727129
·
Ginekol Pol 2017;88(6):307-311.
Affiliations
  1. 2nd Department of Obstetrics and Gynecology, Medical University of Warsaw, Poland, Poland
  2. Department of Immunology, Centre for Biostructure Research, Medical University of Warsaw, Banacha 1a, 02-097 Warsaw, Poland
  3. Department of Obstetrics and Gynecology Didactics, Medical University of Warsaw, Warsaw, Poland
  4. Department of Gynecological Endocrinology, Medical University of Warsaw, Karowa 2, 00-315 Warsaw, Poland
  5. 2nd Department of Obstetrics and Gynecology, Medical University of Warsaw, Poland

open access

Vol 88, No 6 (2017)
ORIGINAL PAPERS Gynecology
Published online: 2017-06-30

Abstract

Objectives: TNF is one of the key cytokines involved in cancer development. TNF signaling can result in both stimulating and inhibitory signals that can result in opposite biological effects in cancerogenesis. 2-(1-adamantylamino)-6-methylpyridine (AdAMP) enhances TNF secretion whereas N-a-tosyl-L-phenylalanine chloromethyl ketone (TPCK) is a NF-κB inhibitor potentially stimulating proapoptotic TNF signals. The aim of the study was to assess the effect of TPCK in combination with AdAMP on human ovarian cells.

Material and methods: CAOV-1 human ovarian cell line was incubated with TPCK and AdAMP for 24 hours. The cytotoxic effect was evaluated in a crystal violet assay. A monoclonal antibody against TNF, Infliximab, was added to examine the possible mechanism of interactions.

Results: Depending on concentration, AdAMP potentialized cytotoxic activity of TPCK or had a synergistic effect with TPCK. Infliximab did not reverse cytotoxicity of AdAMP and TPCK and in some cytotoxic and non-cytotoxic concentrations even enhanced their cytotoxicity.

Conclusions: AdAMP and TPCK cytotoxicity seems to be dependent on TNF signaling, however, the exact mechanism of interactions remains unclear.

Abstract

Objectives: TNF is one of the key cytokines involved in cancer development. TNF signaling can result in both stimulating and inhibitory signals that can result in opposite biological effects in cancerogenesis. 2-(1-adamantylamino)-6-methylpyridine (AdAMP) enhances TNF secretion whereas N-a-tosyl-L-phenylalanine chloromethyl ketone (TPCK) is a NF-κB inhibitor potentially stimulating proapoptotic TNF signals. The aim of the study was to assess the effect of TPCK in combination with AdAMP on human ovarian cells.

Material and methods: CAOV-1 human ovarian cell line was incubated with TPCK and AdAMP for 24 hours. The cytotoxic effect was evaluated in a crystal violet assay. A monoclonal antibody against TNF, Infliximab, was added to examine the possible mechanism of interactions.

Results: Depending on concentration, AdAMP potentialized cytotoxic activity of TPCK or had a synergistic effect with TPCK. Infliximab did not reverse cytotoxicity of AdAMP and TPCK and in some cytotoxic and non-cytotoxic concentrations even enhanced their cytotoxicity.

Conclusions: AdAMP and TPCK cytotoxicity seems to be dependent on TNF signaling, however, the exact mechanism of interactions remains unclear.

Get Citation

Keywords

AdAMP, TPCK, TNF, NF-kB inhibitors, proteasome, ovarian cancer, cell line

About this article
Title

Potentialization of N-a-tosyl-L-phenylalanine chloromethyl ketone (TPCK) cytotoxic activity by 2-(1-adamantylamino)-6-methylpyridine (AdAMP) in human ovarian cancer cells

Journal

Ginekologia Polska

Issue

Vol 88, No 6 (2017)

Article type

Research paper

Pages

307-311

Published online

2017-06-30

DOI

10.5603/GP.a2017.0064

Pubmed

28727129

Bibliographic record

Ginekol Pol 2017;88(6):307-311.

Keywords

AdAMP
TPCK
TNF
NF-kB inhibitors
proteasome
ovarian cancer
cell line

Authors

Jacek Sieńko
Witold Lasek
Justyna Teliga-Czajkowska
Roman Smolarczyk
Krzysztof Czajkowski

References (29)
  1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010; 46(4): 765–781.
  2. Vaughan S, Coward JI, Bast RC, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011; 11(10): 719–725.
  3. Vargas-Hernández VM, Moreno-Eutimio MA, Acosta-Altamirano G, et al. Management of recurrent epithelial ovarian cancer. Gland Surg. 2014; 3(3): 198–202.
  4. Fung-Kee-Fung M, Oliver T, Elit L, et al. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol. 2007; 14(5): 195–208.
  5. Raja FA, Chopra N, Ledermann JA, et al. Targeted trials in ovarian cancer. Gynecol Oncol. 2010; 119(1): 151–156.
  6. Takeyama H, Wakamiya N, O'Hara C, et al. Tumor necrosis factor expression by human ovarian carcinoma in vivo. Cancer Res. 1991; 51(16): 4476–4480.
  7. Ihnatko R, Kubes M. TNF signaling: early events and phosphorylation. Gen Physiol Biophys. 2007; 26(3): 159–167.
  8. MacEwan DJ. TNF receptor subtype signalling: differences and cellular consequences. Cell Signal. 2002; 14(6): 477–492.
  9. Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science. 2002; 296(5573): 1634–1635.
  10. Kazimierczuk Z, Górska A, Switaj T, et al. Adamantylaminopyrimidines and -pyridines are potent inducers of tumor necrosis factor-alpha. Bioorg Med Chem Lett. 2001; 11(9): 1197–1200.
  11. Mauri JK, Lasek W, Górska A, et al. Synthesis, structure and tumour necrosis factor-alpha production-enhancing properties of novel adamantylamino heterocyclic derivatives. Anticancer Drug Des. 2001; 16(2-3): 73–80.
  12. Lasek W, Switaj T, Sieńko J, et al. Stimulation of TNF-alpha production by 2-(1-adamantylamino)-6-methylpyridine (AdAMP) - a novel immunomodulator with potential application in tumour immunotherapy. Cancer Chemother Pharmacol. 2002; 50(3): 213–222.
  13. Ferreira JJ, Rascol O. Prevention and therapeutic strategies for levodopa-induced dyskinesias in Parkinson's disease. Curr Opin Neurol. 2000; 13(4): 431–436.
  14. Khare MD, Sharland M. Influenza. Expert Opin Pharmacother. 2000; 1(3): 367–375.
  15. Basarić N, Sohora M, Cindro N, et al. Antiproliferative and antiviral activity of three libraries of adamantane derivatives. Arch Pharm (Weinheim). 2014; 347(5): 334–340.
  16. Aggarwal S, Takada Y, Singh S, et al. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem. 1995; 270(42): 24995–25000.
  17. Liu SF, Ye X, Malik AB. Inhibition of NF-kappaB activation by pyrrolidine dithiocarbamate prevents In vivo expression of proinflammatory genes. Circulation. 1999; 100(12): 1330–1337.
  18. Gilmore TD, Koedood M, Piffat KA, et al. Rel/NF-kappaB/IkappaB proteins and cancer. Oncogene. 1996; 13(7): 1367–1378.
  19. Shames BD, Selzman CH, Meldrum DR, et al. Interleukin-10 stabilizes inhibitory kappaB-alpha in human monocytes. Shock. 1998; 10(6): 389–394.
  20. Voboril R, Weberova-Voborilova J. Sensitization of colorectal cancer cells to irradiation by IL-4 and IL-10 is associated with inhibition of NF-kappaB. Neoplasma. 2007; 54(6): 495–502.
  21. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003; 101(6): 2377–2380.
  22. Kazimierczuk Z, Górska A, Switaj T, et al. Adamantylaminopyrimidines and -pyridines are potent inducers of tumor necrosis factor-alpha. Bioorg Med Chem Lett. 2001; 11(9): 1197–1200.
  23. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010; 70(2): 440–446.
  24. Knutson KL, Karyampudi L, Lamichhane P, et al. Targeted immune therapy of ovarian cancer. Cancer Metastasis Rev. 2015; 34(1): 53–74.
  25. Pazhang Y, Jaliani HZ, Imani M, et al. Synergism between NF-kappa B inhibitor, celastrol, and XIAP inhibitor, embelin, in an acute myeloid leukemia cell line, HL-60. J Cancer Res Ther. 2016; 12(1): 155–160.
  26. Scallon BJ, Moore MA, Trinh H, et al. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine. 1995; 7(3): 251–259.
  27. Lügering A, Schmidt M, Lügering N, et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology. 2001; 121(5): 1145–1157.
  28. Di Sabatino A, Pender SLF, Jackson CL, et al. Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies. Gastroenterology. 2007; 133(1): 137–149.
  29. Rath PC, Aggarwal BB. TNF-induced signaling in apoptosis. J Clin Immunol. 1999; 19(6): 350–364.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl